Since PPARβ/δ has been suggested as a potential target for metabolic modulation therapy aimed at diabetes-induced cardiomyopathy [36], our study may signal possible adverse effects related to this differential expression of PPARβ/δ in different tissues during diabetes. This evidence concerns the gene PPARD and cardiomyopathy.